Innova Biosciences introduces InnovaCoat GOLD-Carboxyl nanoparticles
Functionalized gold nanoparticles for easy, fast covalent conjugation of antibodies.
Innova Biosciences, a specialist provider of bioconjugation products and services, has launched a carboxylated derivative of its unique InnovaCoat GOLD 40 nm nanoparticles. The new product enables customers to quickly generate highly stable covalent gold-antibody conjugates at R&D and manufacturing scales.
The InnovaCoat GOLD-Carboxyl surface is optimized for single step EDC (1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide) covalent coupling, without signs of aggregation, and eliminates the need for EDC/NHS (N-Hydroxysuccinimide) pre-activation and washing steps associated with traditional conjugations. The process is also significantly faster than standard methods, with conjugates ready to use in less than 35 minutes.
Anna Sereni, Team Leader of Particles at Innova Biosciences, commented: “The InnovaCoat GOLD-Carboxyl nanoparticles build upon Innova’s continuously expanding range of particle technologies, which also includes gold and latex conjugation kits, as well as pre-conjugated gold and colloidal gold. Innova’s broadening product range offers increased flexibility to those working within in-vitro diagnostics, as well as in other industries which utilize nanoparticle technologies.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.